damaging normal tissues. Dendritic cells are specialized antigen-presenting cells that are capable of initiating and polarizing T-cell responses. 3, 23 They have a unique ability to capture antigens and, upon maturation, potently induce antigen-specific T-cell responses, making DCs a potential tool in immunotherapy. Ex vivo, antigen-loaded DCs can be used either to elicit immune responses in vivo or to generate effector T cells ex vivo for adoptive transfer. 17, 36 Initial Phase I studies that have been performed in malignant glioma by using tumor antigen-loaded immature DCs 45, 49, 50 or mature DCs 21, 35 as a vaccine have shown clear evidence of antitumor responses, but the benefits for patients remain to be demonstrated. 46 Vaccination therapy that uses autologous, tumor antigenpulsed DCs requires ex vivo generation of adequate numbers of mature DCs under GMP conditions 38 and relies on patients having functional cellular immunity. Patients who have malignant gliomas and might be candidates for vaccination therapy have already undergone radiotherapy and/ or chemotherapy, and most of them take steroids to prevent tumor-associated edema. All of these factors can influence a patient's immune status 34 and, therefore, could hamper the effectiveness of DC vaccination therapy. In addition, the tumor cells themselves can influence the immune system, resulting in systemic immunosuppression in patients with gli-omas. 13, 31 Glioblastomas secrete various cytokines, including transforming growth factor-␤, 10 IL-6, 42 IL-10, 30 and prostaglandins. 9 These tumor-derived immunoregulatory cytokines not only directly affect T-cell activation, proliferation, and effector function, but they also can interfere with DC maturation and activity. 27, 39, 40, 47 Thus, they may prevent efficient DC generation, particularly that of mature DCs. It is the mature DCs that appear to be required in vaccination therapy, 25 rather than immature DCs, which can cause antigen-specific tolerance. 12 It is currently not well established whether such systemic effects of tumor-or treatment-related changes, which influence the generation of DCs as well as the outcome of such therapy, are present in patients with glioblastoma. For further understanding, we analyzed the immune status and the efficiency of mature DC generation in patients with malignant glioma in comparison with healthy volunteer donors. This study might also help to identify patients who could benefit from DC-based vaccination therapy.
Clinical Material and Methods

Patient and Control Groups
Peripheral blood samples from 26 patients and 23 healthy control donors were obtained after getting informed consent. The therapies and medications that were used are listed in Table 1 . The median time interval between surgery and blood collection in 26 patients was 5.5 days; the mean interval between radiation therapy and blood collection in 15 patients was 7 months; and the mean interval between chemotherapy and blood sample collection in 10 patients was 6.5 months. Median tumor volumes were 42.9 ml before surgery for 15 patients (range 5.5-147.9 ml) and 3.8 ml at close to the time point of analysis in 17 patients (range 0-74.3 ml). Immunocharacterization was performed in 10 men and 11 women, who had a median age of 55 years. Glioblastomas categorized as World Health Organization Grade IV were diagnosed in 17 of these patients, and Grade III anaplastic astrocytomas were diagnosed in four. The eight men and five women in the control group had a median age of 55 years.
The generation of DCs was studied in eight men and seven women who had a median age of 51 years. Glioblastomas categorized as World Health Organization Grade IV were diagnosed in 14 of these patients, and Grade III anaplastic astrocytoma in one. The six men and seven women in the control group had a median age of 31 years, so they were significantly younger than the patients. Although there is no evidence for the DC compartment being affected by age, 22 this age difference may cause a bias toward a better performance of control group members compared with the patients, if it has any effect at all.
Cytokines, mAbs, and Media
The researchers obtained FITC-conjugated mAbs from Beckman Coulter (Krefeld, Germany). These included mAbs specific for CD3 (UCHT1), CD4 (13B8.2), CD8 (B9.11), CD14 (RM052), CD25 (B1.49.9), CD28 (CD28.2), CD45RA (ALB11), CD45R0 (UCHL1), CD80 (MAB104), CD83 (HB15a), and HLA-DR (Immu-357) as well as isotype controls; phycoerythrin-conjugated mAbs specific for CD1a (BL.6), CD3 (UCHT1), CD14 (RM052), CD19 (J4.119), CD56 (NKH-1), and CD83 (HB15a) as well as isotype controls; and nonconjugated mAbs specific for CD14 (RMO52). In addition, FITC-conjugated mAbs specific for CD1a (HI149), CD40 (5C3), CD45 (2D1), and CD86 (FUN-1) and phycoerythrin-conjugated mAbs specific for CD152 (BNI3) and CD154 (TRAP1) were obtained from BD Biosciences (Heidelberg, Germany).
Both TNF␣ and IL-4 were obtained from CellGenix (Freiburg, Germany). Two types of GM-CSF were used: Leucomax 150 (Essex Pharma, Munich, Germany) and Leukine Sargramostim (Berlex, Richmond, CA). Final concentrations of cytokines were 1000 U/ml each.
The culture medium for ex vivo DC generation was X-VIVO 15 medium (Cambrex, Verviers, Belgium) supplemented with 1.5% autologous plasma. Autologous plasma was heat inactivated (30 minutes at 56˚C), sediments were removed by centrifugation (15 minutes at 1880 G and 20˚C), and the plasma was filtered (0.2-m Minisart; Sartorius, Göttingen, Germany) before use. CellGroDC medium was obtained from CellGenix and was used without the addition of serum or plasma.
Enrichment of CD14
ϩ Monocytes
Monocytes were enriched from PBMC by using LS separation columns on a VarioMACS separation unit according to the instructions of the manufacturer (Miltenyi Biotec, Bergisch Gladbach, Germany), as described previously. 37 
Ex Vivo Generation of DCs
Enriched CD14
ϩ monocytes (10 6 cells/ml) were incubated in X-VIVO 15 medium supplemented with 1.5% autologous plasma or CellGroDC medium in the presence of GM-CSF and IL-4 (1000 U/ml each) in 24-well plates (Corning Costar, Wiesbaden, Germany) at 37˚C in 5% CO 2 in a humidified atmosphere. After 3 days of incubation, 1 ml of medium was replaced with 1 ml of fresh medium containing GM-CSF and IL-4 (2000 U/ml each). On Day 6 of incubation, 1 ml of medium was replaced with 1 ml of fresh medium containing GM-CSF, IL-4, and TNF␣ (2000 U/ml each). Cultures were continued until Day 9, when cells were harvested from the 24-well plate, washed, and analyzed.
Cell Counts and Flow Cytometry
Cell counts were determined using an analyzer (Abbott Cell-Dyn 3500; Abbott, Wiesbaden, Germany); viability was determined using trypan blue exclusion and microscopic evaluation.
Immunostaining of blood samples was performed as described previously. 37 Samples were analyzed using a flow cytometer (EPICS XL-MCL or FACS Calibur; Beckman Coulter or BD Biosciences, respectively). Frequencies of leukocyte, T-lymphocyte, and monocyte subpopulations were determined using electronically gated CD45 ϩ leukocytes, CD3
ϩ T lymphocytes, and CD14 ϩ monocytes, respectively.
Stimulation With PHA
To determine mitogen responsiveness, PBMC from three patients ( Table 1) and two control donors (10 6 /ml, 200 l/ well) were cultured in 96-well, round-bottom plates (Grein-er; Nürtingen, Germany) in RPMI-1640 medium (Life Technologies, Karlsruhe, Germany) supplemented with 10% fetal calf serum (Life Technologies), 2 mM L-glutamine (Cambrex), 100 U/ml penicillin, and 100 g/ml streptomycin (Cambrex) in the presence or absence of 5 g/ml PHA-M (Sigma-Aldrich Co., Taufkirchen, Germany). After two days of incubation, cells were pulsed with BrdU for 16 hours, and BrdU uptake was determined using the BrdU enzyme-linked immunosorbent assay kit as recommended by the manufacturer (Roche Diagnostics, Mannheim, Germany).
Statistical Analysis
All data are presented as the mean Ϯ SEM unless stated otherwise. Statistical analysis was performed using the nonparametric Mann-Whitney U-test. For comparison of DC generation in plasma-supplemented and serum-free media, the paired Student t-test was used. Probability values less than or equal to 0.05 were considered statistically significant.
Results
Immunocharacterization of Glioma Patients and Healthy Normal Donors
Blood cell counts, white blood cell subpopulations, and the expression of relevant immunoregulatory molecules on T cells and monocytes were studied in patients with glioma and in healthy control volunteers. Results are summarized in Fig. 1 and Table 2 .
Frequencies of lymphocytes (28.6 Ϯ 1.6% and 19.0 Ϯ 1.7% for control and patient groups, respectively; p Ͻ 0.001), CD3 ϩ T cells (28.9 Ϯ 2.2% and 17.3 Ϯ 2.6% for control and patient groups, respectively; p = 0.003), and CD19 ϩ B cells (4.6 Ϯ 0.7% and 2.4 Ϯ 0.5% for control and patient groups, respectively; p = 0.011) were significantly lower in the patient group. However, frequencies of neutrophils (60.7 Ϯ 1.9% and 70.7 Ϯ 2.3% for control and patient groups, respectively; p = 0.005) and CD14 ϩ monocytes (5.4 Ϯ 0.4% and 6.9 Ϯ 0.5% for control and patient groups, respectively; p = 0.028) were significantly higher in the patient group (Fig. 1A ). There were no significant differences between the two groups in frequencies of CD56 ϩ NK T cells and NK cells (Fig. 1 ). The differences in frequencies translated to a trend in patients toward lower absolute cell counts for lymphocytes and B cells (2.0 Ϯ 0.2 ϫ 10 6 cells/ml compared with 1.6 Ϯ 0.2 ϫ 10 6 cells/ml and 0.3 Ϯ 0.1 ϫ 10 6 cells/ml compared with 0.2 Ϯ 0.1 ϫ 10 6 cells/ml for control and patient groups, respectively) and a significant reduction of CD3 ϩ T-cell numbers (2.0 Ϯ 0.2 ϫ 10 6 cells/ml compared with 1.3 Ϯ 0.2 ϫ 10 6 cells/ml for control and patient groups, respectively; p = 0.039). However, the total white blood cell counts and numbers of neutrophils, NK cells, and monocytes were not significantly different between the patient and control groups (data not shown).
The median tumor volume in 12 patients at the time of analysis (postsurgery) was 1.9 ml. When the immune status was compared for patients with tumor volume that was above or below the median, there were no significant differences between the two groups in the frequencies of CD3 (Fig. 1C) showed a significant reduction in the frequencies of CD80 ϩ monocytes for patients (72.3 Ϯ 5.5% and 39.8 Ϯ 9.7% for control and patient groups, respectively; p = 0.015) as well as CD86 ϩ monocytes (94.8 Ϯ 2.3% and 85.7 Ϯ 4.7% for control and patient groups, respectively; p = 0.029). There were no significant differences between the two groups in the frequencies of CD40 ϩ and HLA-DR ϩ monocytes. When the density of expression of these molecules on monocytes was analyzed, no significant differences were observed between the patient and control groups (data not shown).
Stimulation With PHA
To compare lectin responsiveness, PBMCs from three patients with glioblastomas and two healthy controls were stimulated with PHA, and BrdU incorporation was determined after 3 days. The PHA responsiveness was comparable for the patients and healthy controls (Fig. 2) .
Ex Vivo Generation of DCs
Monocytes from 15 patients with malignant gliomas and 13 healthy donors were differentiated to DCs in X-VIVO 15 medium supplemented with 1.5% heat-inactivated autologous plasma in the presence of GM-CSF and IL-4 for the first 6 days of incubation, followed by an additional 3-day incubation period in the presence of TNF␣, GM-CSF, and IL-4 to induce DC maturation. Following immunomagnetic enrichment on Day 0, CD14 ϩ monocytes accounted for 98.2 Ϯ 0.2% of all cells for 10 control samples and 98.0 Ϯ 0.5% of all cells for 15 patient samples. The differentiation and maturation of the DCs were evaluated after 9 days of incubation by using flow cytometric enumeration of CD14, CD1a, and CD83 positive cells as well as analysis of CD40, CD80, CD86, and HLA-DR expression.
The differentiation of monocytes to DCs was associated with downregulation of the monocyte marker CD14 and upregulation of the mature DC-associated CD83 antigen ( Fig.  3A and B ). There were no significant differences between the control and patient groups in the frequencies of mature CD83
ϩ DCs (24.3 Ϯ 6.7% compared with 34.1 Ϯ 7.3%), residual CD14 ϩ monocytes (20.8 Ϯ 4.6% compared with 14.1 Ϯ 4.2%), and CD1a ϩ DCs (5.1 Ϯ 1.7% compared with 5.5 Ϯ 1.2%) (Fig. 4A ). There were also no differences in CD40, CD86, and HLA-DR expression (Figs. 3C and 4C ), all of which were positive on the majority of cells, whereas expression of CD80 was significantly higher for the 10 patient samples compared with the 13 control samples (59.8 Ϯ 6.5% and 40.7 Ϯ 5.8%, respectively; p = 0.044). Overall cellular recovery (Fig. 4B) was not different between the patient and control groups. In addition, no differences were observed between the two groups when the outputs of CD83 ϩ mature DCs and residual CD14 ϩ monocytes were calculated for an input of 10 6 CD14 ϩ monocytes. When cultures were performed in CellGroDC serum-free medium (Fig. 5) instead of autologous plasma-supplemented X-VIVO 15 medium (Fig. 4) , no significant differences were seen between patient and control group in frequencies of CD83
, and CD86 ϩ cells; in the cellular outputs of CD14 ϩ and CD83 ϩ cells; or in overall recovery (Fig. 5) . The only exception was a higher frequency of HLA-DR ϩ cells observed for 10 patients compared with 13 healthy controls (85.2 Ϯ 3.3% and 95.0 Ϯ 1.9% in control and patient groups, respectively; p = 0.026). However, when the results of ex vivo DC generation were compared between the two media for all samples from patients and healthy controls combined (Fig.  6) , serum-free CellGroDC medium showed superior results compared with plasma-supplemented X-VIVO 15 medium in the generation of mature DCs, with a significantly higher frequency of CD83 Patients had a median tumor volume of 10 ml at close to the time point of analysis. When DC generation was compared for patients with a tumor volume that was above or below the median, there were no differences between the two groups in the frequencies of CD14 ϩ and CD83 ϩ cells for plasma-supplemented and serum-free culture systems (data not shown).
Discussion
The immune status of patients with gliomas revealed several differences when compared with that of healthy controls. Patients were lymphopenic due to a significantly reduced frequency of T cells. Relative frequencies of the major CD4 ϩ helper and CD8 ϩ cytotoxic T-cell subsets, however, were normal, suggesting that the reduction of T cells is more general rather than subset restricted. The occurence of T-lymphopenia is well documented in patients with malignant glioma. 13 It has been attributed to T-cell apoptosis 28 or reduced thymic output, 33 whereas mild neutrophilia observed in such patients may be due to glioma cells producing granulocyte colony-stimulating factor. 19 In contrast to T cells, frequencies of NK cells were in a normal range, which is consistent with earlier reports. 2, 4 Recently, Dhodapkar and colleagues 11 have shown that functionally competent NK T cells are also present at normal frequencies and numbers in glioma patients. Thus, immunological changes associated with malignant glioma appear mainly to affect the T-cell compartment.
In the patients, T cells showed a normal expression of CD4, CD8, CD25, CD28, CD45RA, CD45R0, CD56, and HLA-DR, again arguing for a more general depletion of T cells. Differences in CD4 and CD28 expression, which have been reported by others, 4, 13 were not evident in the patients in this study.
Functionally, T cells revealed normal responsiveness to PHA stimulation, which is in contrast to previous reports, documenting a state of anergy and reduced responses to mitogens or anti-CD3 stimulation of T cells in patients with malignant gliomas. 1, 5, [14] [15] [16] The reason for this difference is not clear, but several studies have indicated that glioma-as-sociated immunosuppression correlates with the size of the tumor and that surgical cytoreduction can restore T-cell responsiveness, at least partially. 6, 7, 29 At the time point of analysis, the patients in this study had already undergone cytoreduction to produce generally lower tumor volume (median of 3.8 ml for all patients) and there were no differences in leukocyte subsets observed among patients with a residual tumor volume that was higher or lower than the median. This not only points out the potential importance of surgery prior to immunotherapy to restore the immune system of patients with malignant glioma, but also the importance of prescreening patients to identify general immunological parameters (for example, immune status, DC differentiation, PHA responsiveness, and delayed-type hypersensitivity responses) that may affect the outcome of therapy. Furthermore, although numbers are still small, the cellular composition of blood cells did not appear to be affected substantially by the intake of steroids or temozolomide by patients (data not shown).
Interestingly, immunological defects in patients with gliomas may not be intrinsic only to T cells. At least partial restoration of immunoresponsiveness has been reported for enriched T-cell populations that were depleted of potential suppressor or accessory cells. 26, 44 On the other hand, Morford and associates 28 have shown that monocytes pretreated with glioma cell-conditioned medium cause T-cell apoptosis. Thus, the monocyte compartment may also play an important role. In our study, patients with malignant glioma showed a significantly reduced frequency of CD80 ϩ (B7.1) and CD86 ϩ (B7.2) monocytes. Thus, expression of two molecules was reduced on monocytes that constitute the essential costimulatory Signal 2 of T-cell activation, in the absence of which T cells become anergic or die from apoptosis. 18 Consistent with this observation, reduced expression of CD80, CD86, HLA class II, and IL-12 as well as increased expression of IL-10 has been reported previously for monocytes treated with glioma cell-conditioned medium in vitro. 51 Monocytes under examintion in this study did not reveal a lower expression of HLA class II, which has been shown by others. 43 However, as was observed in the T-cell compartment, tumor resection results in at least partial normalization of monocytes.
In addition to sufficiently functional cellular immunity, ex vivo generation of adequate numbers of mature DCs is another prerequisite for the effective use of DC-based vaccination immunotherapy. Monocyte-derived DCs are most frequently used in clinical studies. It is well established that mature, rather than immature, DCs should be used as a vaccine, 25 particularly because it has been reported that immature DCs, which had been used in initial vaccination trials, can cause antigen-specific tolerance. 12 Monocytes can be easily enriched to high purity suitable for clinical application in sufficient numbers in a closed system. Two-step culture protocols are available that allow predefined successive generation of immature and mature DCs for antigen loading and vaccination, respectively. 38 However, in patients with malignant glioma such protocols may be impaired, either by the tumor itself or as a result of previous therapies. In such patients, the monocyte compartment is affected (Fig.  1C) , 43, 51 and DCs themselves may also present a target. For example, DCs injected into rat 9L gliosarcomas undergo apoptosis caused by the tumor extracellular matrix component hyaluronan via the induction of inducible nitric oxide synthase and nitric oxide production. 48 Furthermore, glioma cells interfere actively with immature DC function, causing downregulation of antigen-uptake activity and of expression of CD54 (ICAM-1), CD80 (B7.1), CD86 (B7.2), and HLA classes I and II. 20 Due to these in vitro observations together with systemic immunosuppression in patients, which appears to be a direct effect of tumor cell secreted factors, it seems likely that the plasma of patients contains factors that interfere with ex vivo DC generation. Protocols for ex vivo DC generation for clinical application require at least GMPgrade reagents and media that are preferably free of animal-derived components. 38 Therefore, autologous plasma is used in many protocols as a media supplement. 21, 38, 45, 50 In malignant glioma, however, this approach seems questionable and needs to be tested in small-scale vaccine production for individual patients prior to large-scale application, FIG. 3. Graphs showing frequencies and immunophenotypes of monocytes (A) and mature DCs (B and C) obtained in patients with glioma. Expression of CD14 and CD83 on immunomagnetically enriched monocytes (A) and after a 9-day tissue culture in plasmasupplemented X-VIVO 15 medium in the presence of GM-CSF and IL-4 for the first 6 days, followed by an additional 3-day incubation period in the presence of GM-CSF, IL-4, and TNF␣ (B) was determined by flow cytometry. Expression of CD40, CD80, CD86, and HLA-DR after a 9-day tissue culture was also determined by flow cytometry (C). Quadrants in A and B were set according to isotype controls, which are also shown as gray histograms (C). Frequencies of CD14 ϩ and CD83 ϩ cells are indicated.
not only because of the patient's plasma potentially containing immunosuppressive factors, but also because of the use of steroid medication in patients with glioma to prevent tumor-associated edema. Dexamethasone has been reported to interfere with DC differentiation and maturation. 24, 32 Alternatively, serum-and plasma-free culture systems have to be established.
When monocytes from patients and healthy controls were cultured in the presence of 1.5% heat-inactivated, autologous plasma-supplemented X-VIVO 15 medium using a protocol reported previously, 38 the ex vivo generation of DCs was comparable for patients and controls, other than a slightly increased expression of CD80 in the patients. Thus, despite the presence of plasma potentially containing immunosuppressive factors and despite a potential bias toward better performance by members of the control group due to their significantly younger age, DC differentiation and, particularly, maturation in patients were normal. When the plasma-supplemented culture system was replaced by a serum-free culture system, again, other than a slightly in- creased expression of HLA-DR, no differences between patients and controls were observed. However, differentiation and maturation of DCs under serum-free conditions using GMP-grade CellGroDC medium, which does not require any cell culture supplements other than cytokines, resulted in high purity ex vivo generation of mature CD83 ϩ and CD14
Ϫ DCs that expressed the costimulatory molecules CD40, CD80, and CD86 as well as HLA-DR at high densities. Therefore, they should be well suited for DCbased immunotherapy for patients with malignant gliomas, even those who have had radio-or chemotherapy, are taking steroid medication, or have grim prognoses. No differences were observed among patients with residual tumor volume that was higher or lower than the median. Thus, it appears to be possible to overcome or at least to reduce tumor-induced systemic immunosuppression in malignant glioma by cytoreduction and to generate mature DC efficiently ex vivo for vaccination therapy. However, whether this will be sufficient to overcome the local immunosuppressive or immunomodulating effects of the tumor cells remains to be determined. Such effects are at least partially mediated by the production of transforming growth factor-␤ 10 and prostaglandin E 2 by gliomas 9 but may also include other immune escape strategies developed in the course of immunoediting of the tumor, all of which may hamper the effector arm of antitumor immunity in immunotherapy.
Conclusions
Following cytoreductive surgery, chemotherapy, and radiotherapy, patients with gliomas revealed only minor immune defects, which probably would not prevent the effective use of an active immunotherapy. These minor immune defects include lymphopenia, mainly due to a general reduction of all T-cell subsets, and the reduced expression of the costimulatory molecules CD80 (B7.1) and CD86 (B7.2) on monocytes. Despite these differences, monocytes of patients could be differentiated and matured in a two-step culture system and could generate mature dendritic cells in normal numbers that have immunophenotypes similar to those of healthy control volunteers. Thus, efficient ex vivo generation of mature DCs in patients with glioma is possible, particularly when serum-free medium suitable for GMP production of DCs is used. Nevertheless, all patients considered for DC vaccination therapy should be prescreened. For example, determination of their immune status, lectin and delayed-type hypersensitivity responses, and DC differentiation and maturation could help determine whether successful vaccine generation is possible and identify more general parameters that could affect the outcome of the therapy.
